Xu Zhenyu sold $38K of SOPH
Xu Zhenyu (Chief Scientific Officer) sold 7,393 shares of SOPHiA GENETICS SA (SOPH) at $5.17 on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and total value by the company’s Chief Scientific Officer under a pre-arranged 10b5-1 plan.
Market read
Confirms a $38.2k insider sale at SOPH under a 10b5-1 plan; typically low incremental trading signal.
What to watch
The filing does not state tax/portfolio needs or whether other insiders are selling/buying; without broader insider flow context, the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA Genetics (SOPH).
Ticker impact
SOPHiA Genetics disclosed Chief Scientific Officer Xu Zhenyu sold 7,393 shares at $5.1727 on a 10b5-1 plan, totaling $38,241.77.
Likely minimal near-term impact; any reaction should be muted given the pre-arranged 10b5-1 structure.
The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and the article contains no accompanying operational/regulatory catalyst.
Market effects
No sector read-across; this is a single-company insider liquidity disclosure.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still coincide with perceived valuation risk; traders may watch for clustering of sales around specific events.
Key entities
- issuerSOPHiA GENETICS SA
Company whose insider transaction was disclosed on Form 4.
- insiderXu Zhenyu
Chief Scientific Officer who reported the sale.
- trading mechanism10b5-1 plan
Pre-arranged plan cited as Yes, reducing interpretive weight of the sale.
